Aggregated price index with volume information
Summary:
- Pharmaceuticals: Other stocks up 0.4% on average while median return up 0.0% in a day
- Pharmaceuticals: Other stocks up 7.1% on average while median return up 3.2% in a week
- Pharmaceuticals: Other stocks up 2.5% on average while median return up -0.7% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $SAVA 180.1%, $RVNC 81.4%, $HROW 58.3%, $OGI 27.8%, $OPT 24.2%
- 1M losers are : Losers for past month are $BHC -22.4%, $SLN -22.7%, $SAGE -33.1%, $IRWD -34.8%, $PCRX -36.0%
- 1W winners are : Winners for past week are $RVNC 87.5%, $OGI 40.8%, $SAVA 30.5%, $VRNA 21.5%, $SIGA 20.7%
- 1W losers are : Losers for past week are $UTHR -2.8%, $OCUL -2.8%, $CPIX -4.8%, $SLN -5.0%, $KALV -7.0%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 13.3%, for the past 3 months is 8.9%
In the past month for a 5 days rolling window, the highest corrrelation is 26.5%, the lowest correlation is 7.0%, the latest correlation is 16.1%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 80.0% between AMPH and HROW
The lowest correlation is -81.1% between HROW and IRWD
The companies’ thermal burn treatment, NexoBrid, has been approved as a non-surgical solution for managing severe burn injuries in both paediatric and adult burn patients.
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
PACE Program Provides Highly Coordinated Personalized Senior Care in Partnership with Eskaton and Adventist HealthSACRAMENTO, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), celebrated the fourth anniversary of its Sacramento, California center with community members, local represen
The analysts might have been a bit too bullish on Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ), given that the company...
The study did not meet its primary endpoint of a statistically significant improvement.
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All AgesYAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) allowing for eschar removal in pediatric patients aged newborn through eighteen with dee
BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-execut
Top Midday Decliners